Pediatric arrhythmology deals with studying of frequency and regularity of heart rhythm disorders in childhood. Rhythm disturbances (dysrhythmias, arrhythmias) occur as a result of disturbances in the creation or conduction of stimuli in the specific or working musculature of the heart. Simplifying the knowledge of everyday work on pediatric arrhythmias, they can originate from the atria of the heart when we speak about supraventricular arrhythmias or from the heart chambers when we talk about ventricular arrhythmias. There are currently three major problems that burden pediatric cardiologists and pediatric arrhythmologists, and which are the focus of interest in pediatrics as a whole. These are primarily sudden cardiac death in children (SCD), fetal arrhythmias (FA) and postoperative-incisional arrhythmias (IA). The development of pediatric arrhythmology is imperative in the development of pediatrics and pediatric cardiology.

Cardiomyopathies (CMP) are very rare disease in newborn with a very poor uotcome. Only isolated case reports and small case series have been reported. CMP is a disease that affects the myocardium and causes mechanical or electrical cardiac dysfunction. Even cumulatively, these conditions account for only approximately 1% of childhood cardiac disease. CMP presents a therapeutic challenge for the clinician, as evidenced by the fact that 10% of all pediatric cardiac deaths can be attributed to this condition. The estimated incidence of pediatric CMP was determined to be 1,13 cases per 100.000 children. Incidence varied according to sex, region and racial origin.We concluded that the best approach for evaluating a neonate who has a potential CMP is to identify the possible type of CMP and subsequently determine the potential cause wich leads terapeutic issue. Aetiology and clinical course are especially heterogeneous in infants. The most commonly identified aetiologies are genetic syndromes and metabolic diseases. A multidisciplinary approach is recommended for defining the aetiology and developing individual treatment strategies.

Objective - The purpose of this investigation was to determine the frequencies and types of associated congenital heart disease and other cardiac lesions in children with congenital anomalies of the kidneys and urinary tract (CAKUT). Participants and method - This was a prospective cardiac evaluation of children with diagnosed CAKUT, conducted between January 2013 and December 2015 at the Department of Pediatrics of the University Clinical Hospital, Tuzla. All cases were reviewed for age, gender, consanguinity, occurrence of congenital heart disease (CHD) and CAKUT in family history. Cardiac examination included: physical examination, noninvasive blood pressure measurement, a twelve lead electrocardiogram and echocardiogram. Results - Complete cardiac examination was performed in 144 children with congenital anomalies of the kidneys and urinary tract. Clinically insignificant morphological or hemodynamical changes were noted in 13% or 9.0% children. Congenital heart disease was found in 32 (22.2%), hypertrophic cardiomyopathy in 2 and pulmonary hypertension in 1 of the 144 children. In 4 children congenital heart disease was part of other known genetic syndromes, and all of these cases had severe CHD. In twenty-six or 76.5% of the total of 32 patients it was already known, and in 6 (23.5%) CHD was discovered during this research. Ventricular septal defect was the most common malformation (13% or 40.6% of patients). Vesicoureteral reflux was the most frequent CAKUT associated with CHD. Conclusions - The results of this study showed a significant association between CAKUT and CHD. Therefore we suggest performing cardiac assessment of all children with CAKUT.

Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. Methods: Observational study, based on 4 sites in Bosnia and Herzegovina (BH 365 (61.9%) infants in total were born before 33 weeks. Average gestational age of preterm infants enrolled for prematurity only was 30.2 ± 3.2 weeks; for preterm infants with BPD/CLD it was 28.3 ± 3.7 weeks. Overall average of palivizumab injections was 4.1 ± 1.0. Hospitalization rate related to severe lower respiratory infections (LRI) during the period of protection by palivizumab was 1.2%. Respiratory infections which deserved medical attention were observed in 3.7% infants included in palivizumab prophylaxis.Conclusion: RSV prophylaxis in B&H is provided systematically and successfully, following the national guidance established in 2009, with the aim of achieving a good cost-benefit ratio, with very low hospitalization rate for severe LRI in prophylaxed infants. New randomized controlled trials (RCTs) and American Academy of Pediatrics (AAP) guidance revised in 2014 will be taken into account in establishing a new national recommendation.

A 6.6-year-old girl presented for leftsided cardiac enlargement on chestradiography (Panel A). Th ree yearsearlier she had undergone a lobectomyof the lower lobe of the leftlung for extraction of an echinococcalcyst.